Abstract: The present invention relates to methods and kits for prognosing, treating, and managing treatment of cancer in a subject. The methods involve selecting a subject having cancer and obtaining, from the selected subject, a sample containing exosomes or an S100 molecule containing sample. The exosomes or S100 molecule containing sample, respectively, are then contacted with one or more reagents suitable to detect higher or lower levels or the presence or absence of one or more integrins on said exosomes or higher or lower levels or the presence or absence of one or more S100 molecules in the S100 molecule containing sample. The cancer is then prognosed, treatment is administered, or treatment is managed.

Abstract: Described herein are monomers capable of forming a biologically useful multimer when in contact with one, two, three or more other monomers in an aqueous media. In one aspect, such monomers may be capable of binding to another monomer in an aqueous media (e.g. in vivo) to form a multimer, (e.g. a dimer). Contemplated monomers may include a ligand moiety, a linker element, and a connector element that joins the ligand moiety and the linker element. In an aqueous media, such contemplated monomers may join together via each linker element and may thus be capable of modulating one or more biomolecules substantially simultaneously, e.g., modulate two or more binding domains on a protein or on different proteins.

Abstract: Cross-linked polymer networks that are at least partially conjugated (e.g., phenylene vinylene polymer networks). The cross-linked polymer networks may be thin-films disposed on a substrate. The cross-linked polymer network may be covalently bonded to the substrate. The cross-linked polymer networks can be used, for example, in methods of detecting explosives (e.g., RDX (cyclotrimethylenetrinitramine)) and degradation products thereof.

Abstract: The various examples presented herein are directed to compounds of the formula A-L1-Het1-L2-Cy1 or a pharmaceutical acceptable salt, polymorph, prodrug, solvate or clathrate thereof, wherein: A is cycloalkyl, aryl, arylalkyl or heterocyclyl; Het1 is heterocyclyl containing at least two heteroatoms; Cy1 is a heterocyclyl; L1 is a bond, alkyl, alkenyl or alkynyl linker; L2 is an acyl or alkyl linker; and A and Cy1 are different. The compounds are useful in the treatment of fibrotic diseases, abnormal vascular leak and pathological angiogenesis.

Abstract: The present disclosure relates to, inter alia, a green technology for crosslinking protein molecules for various uses, where the protein molecules can be contained in protein fibers such as, but not limited to, human hair, animal fibers, and mixtures thereof. In one aspect, the present disclosure relates to a crosslinking agent comprising an oxidized sugar having at least two aldehyde groups. In another aspect, the present disclosure relates to a method of crosslinking protein fibers. This method involves providing the aforementioned crosslinking agent and infiltrating a plurality of non-crosslinked protein fibers with the crosslinking agent under conditions effective to cause protein molecules contained in the non-crosslinked protein fibers to become crosslinked, thereby yielding a population of crosslinked protein fibers.

Abstract: A PET imaging system, with parallel detector rings sharing a common axis (e.g., rings with one or more detector elements in the axial direction and two or more detector elements in the transaxial direction), may have an adaptive axial and/or transaxial FOV by employing a sparse detector configuration and adapting the size of axial gaps between rings and/or the size of transaxial gaps between detector elements in each ring. The axial FOV may be dynamic, enabling PET data acquisition in multiple modes (e.g., “retracted” with detector rings in a compact configuration, and “extended” with detector rings extended for longer axial FOV). The transaxial FOV may be dynamic, enabling an adaptive detector ring diameter for different body part contours. The sparse detector ring configurations may be used to extend the scanner axial and/or transaxial FOV, or retain the current system's FOV with half the number of (or otherwise fewer) detector elements.

Abstract: Provided are compounds, compositions and methods for inhibiting fascin activity or treating a condition or disorder mediated by fascin activity in a subject in need thereof.

Abstract: A system for measuring synchrony between two or more regions, or within a single region, of a subject's brain. The system can include a signal conditioning module in communication with a phase extraction module. The signal conditioning module can receive an oscillating signal, bandpass filter the signal, and convert the signal to its real and imaginary components. The phase extraction module can receive the real and imaginary components, determine the quadrant of the oscillating signal on the complex plane based on the real and imaginary components, and determine the phase of the oscillating signal using a linear arctangent approximation based on the determined quadrant. The system can calculate synchrony metrics based on the determined phase.

Abstract: A computer implemented method can optimize classification of patients from large patient datasets. The method includes extracting, from data structures of different data sources, data related to a large plurality of patient. Patient electronic health record (EHR) data are linked across the data sources in a privacy preserving manner to generate patient information for the patient. Based on patient information for a selected patient, a high-cost status, a phenotype, and a persistence property of the selected patient are generated. The persistence property is one or both of a persistently high cost or a persistently high utilization. Furthermore, a high-cost status, a phenotype, and a persistence property are applied to a machine learning model to determine at least one risk score for the selected patient. The machine learning model is trained using training data related to the large plurality of patients.

Abstract: In some implementations, the present solution can determine a first structural vector of a first chemical based on a chemical structure of the first chemical. The system can also determine first target vector of the first chemical based on at least one gene target for the first chemical. The system can use the structural vector and the target vector to generate a toxicity predictor score for the first chemical.

Abstract: The present disclosure is directed to novel nucleoside analog compounds and methods for treating diseases characterized by high expression levels of adenosine kinase (ADK).

Abstract: A multiplex assay with an improved sensitivity and specificity for the diagnosis of Brucella canis infection in mammals using two specific antigens (BP26 and Omp31pep) is disclosed. Also disclosed are kits for detecting immune responses to a Brucella canis infection, methods of detection, methods for monitoring progression and methods for treating a Brucella canis infection.

Abstract: A system and method for adaptive illumination, the imaging system comprising an excitation source having a modulator, which generates a pulse intensity pattern having a first wavelength when the excitation source receives a modulation pattern. The modulation pattern is a data sequence of a structural image of a sample. An amplifier of the imaging system is configured to receive and amplify the pulse intensity pattern from the modulator. A frequency shift mechanism of the imaging system shifts the first wavelength of the pulse intensity pattern to a second wavelength. A laser scanning microscope of the imaging system receives the pulse intensity pattern having the second wavelength.

Abstract: Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a subject. Moreover, IRE1 small molecule inhibitors described herein are for the treatment of cancer, where the cancer is a solid or hematologic cancer.

Abstract: A surgical barrier material comprising a water-soluble polysaccharide, glycerol, and water, wherein the water-soluble polysaccharide by weight and glycerol by volume are present at a ratio of about 1:0.8 to 1:1.2, and wherein water is present at 8-20 wt %, wherein the water-soluble polysaccharide may be, for example, a cellulose, such as methyl cellulose, carboxymethylcellulose or a salt thereof (CMC), hyaluronic acid (HA) or a combination thereof and may have a molecular weight of 30,000 g/mol to 500,000 g/mol. The surgical barrier material is solid and flexible, typically possessing an elastic modulus of 0.5-2 MPa and penetration resistance of at least 1 Newton, and substantially dissolves within 72, 48, 24, 12, 6, 3, or 2 hours from the time it is placed at a surgical site. Also described herein is a method of preventing injury to tissue in a patient during a surgical procedure by using the described surgical barrier material as a protective barrier during the surgical procedure.

Abstract: A method for controlling connectivity between two or more brain regions of a subject includes receiving signals corresponding to a connectivity between two or more regions of a subject's brain, measuring a connectivity level from the signals, and delivering at least one stimulation pulse to at least one target region of the subject's brain if the measured connectivity level is outside of a predetermined range.

Abstract: The present invention relates to an article fabrication system having a plurality of material deposition tools containing one or more materials useful in fabricating the article, and a material deposition device having a tool interface for receiving one of the material deposition tools. A system controller is operably connected to the material deposition device to control operation of the material deposition device. Also disclosed is a method of fabricating an article using the system of the invention and a method of fabricating a living three-dimensional structure.

Abstract: Described herein is a method of induced cell death via ferroptosis by nanoparticle ingestion. Moreover, the present disclosure describes the administration of high concentrations of ultrasmall nanoparticles at multiple times over the course of treatment in combination with a nutrient-depleted environment, thereby modulating cellular metabolic pathways to induce cell death by the mechanism ferroptosis. Ferroptosis involves iron, reactive oxygen species, and a synchronous mode of cell death execution.

Abstract: The present disclosure provides methods for forming stable three-dimensional vascular structures, such as blood vessels and uses thereof. More specifically, the present disclosure provides methods for culturing differentiated endothelial cells that include an exogenous nucleic acid encoding ETV2 transcription factor on a matrix under conditions that express exogenous ETV2 protein in the endothelial cell to form stable three-dimensional artificial blood vessels without the use of a scaffold, pericytes or perfusion. The present disclosure also provides stable three-dimensional blood vessels that are capable of autonomously forming a functional three-dimensional vascular network, and uses thereof.

Abstract: The invention is a new and distinct variety of grapevine plant named ‘ARAVELLE’, which is characterized by its adaptability to the Finger Lakes grape production region of New York and similar regions; fruit suitable for production of wines; moderate resistance to downy and powdery mildews; and resistance to Botrytis bunch rot.